AU2021291128A1 - Use of cannabidiol in the treatment of epilepsy - Google Patents
Use of cannabidiol in the treatment of epilepsy Download PDFInfo
- Publication number
- AU2021291128A1 AU2021291128A1 AU2021291128A AU2021291128A AU2021291128A1 AU 2021291128 A1 AU2021291128 A1 AU 2021291128A1 AU 2021291128 A AU2021291128 A AU 2021291128A AU 2021291128 A AU2021291128 A AU 2021291128A AU 2021291128 A1 AU2021291128 A1 AU 2021291128A1
- Authority
- AU
- Australia
- Prior art keywords
- cbd
- caffeine
- cannabidiol
- day
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2009321.7A GB202009321D0 (en) | 2020-06-18 | 2020-06-18 | Use of cannabinoids in the treatment of epilepsy |
| GB2009321.7 | 2020-06-18 | ||
| PCT/GB2021/051520 WO2021255446A1 (en) | 2020-06-18 | 2021-06-16 | Use of cannabidiol in the treatment of epilepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021291128A1 true AU2021291128A1 (en) | 2022-12-01 |
Family
ID=71838306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021291128A Pending AU2021291128A1 (en) | 2020-06-18 | 2021-06-16 | Use of cannabidiol in the treatment of epilepsy |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230225986A1 (https=) |
| EP (1) | EP4167980B1 (https=) |
| JP (1) | JP2023530500A (https=) |
| KR (1) | KR20230026337A (https=) |
| CN (1) | CN115916168A (https=) |
| AU (1) | AU2021291128A1 (https=) |
| CA (1) | CA3181694A1 (https=) |
| GB (2) | GB202009321D0 (https=) |
| MX (1) | MX2022016038A (https=) |
| TW (1) | TW202214217A (https=) |
| WO (1) | WO2021255446A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| AU2024300440A1 (en) * | 2023-07-25 | 2026-03-12 | Algorae Pharmaceuticals Ltd | Compositions and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015308546A1 (en) * | 2014-08-25 | 2017-04-13 | Clk Consult V/ Carsten Leonhard Knudsen | Device with compositions for delivery to the lungs, the oral mucosa and the brain |
| GB2531282A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) * | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US20180360771A1 (en) * | 2017-06-14 | 2018-12-20 | Yury Leon Shmerlis | Cannabidiol chewing gum |
| GB2568471B (en) | 2017-11-15 | 2022-04-13 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| CN109985042A (zh) * | 2017-12-29 | 2019-07-09 | 汉义生物科技（北京）有限公司 | 一种含有大麻二酚或大麻提取物和咖啡因的组合物及其应用 |
| US20200172841A1 (en) * | 2018-12-04 | 2020-06-04 | Donald F. Wilkes | Alcohol-free wine beverage |
-
2020
- 2020-06-18 GB GBGB2009321.7A patent/GB202009321D0/en not_active Ceased
-
2021
- 2021-06-16 JP JP2022578719A patent/JP2023530500A/ja active Pending
- 2021-06-16 MX MX2022016038A patent/MX2022016038A/es unknown
- 2021-06-16 US US18/002,437 patent/US20230225986A1/en active Pending
- 2021-06-16 AU AU2021291128A patent/AU2021291128A1/en active Pending
- 2021-06-16 KR KR1020227044124A patent/KR20230026337A/ko active Pending
- 2021-06-16 CN CN202180042463.2A patent/CN115916168A/zh active Pending
- 2021-06-16 WO PCT/GB2021/051520 patent/WO2021255446A1/en not_active Ceased
- 2021-06-16 CA CA3181694A patent/CA3181694A1/en active Pending
- 2021-06-16 EP EP21736654.1A patent/EP4167980B1/en active Active
- 2021-06-17 TW TW110122055A patent/TW202214217A/zh unknown
- 2021-06-17 GB GB2108690.5A patent/GB2598187A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP4167980A1 (en) | 2023-04-26 |
| CA3181694A1 (en) | 2021-12-23 |
| KR20230026337A (ko) | 2023-02-24 |
| CN115916168A (zh) | 2023-04-04 |
| GB202009321D0 (en) | 2020-08-05 |
| TW202214217A (zh) | 2022-04-16 |
| WO2021255446A1 (en) | 2021-12-23 |
| MX2022016038A (es) | 2023-02-02 |
| GB202108690D0 (en) | 2021-08-04 |
| US20230225986A1 (en) | 2023-07-20 |
| GB2598187A (en) | 2022-02-23 |
| JP2023530500A (ja) | 2023-07-18 |
| EP4167980B1 (en) | 2025-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lipton et al. | Caffeine in the management of patients with headache | |
| JP6014083B2 (ja) | 眠気覚まし用組成物 | |
| US11707465B2 (en) | Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine | |
| EP4167980B1 (en) | Use of cannabidiol in the treatment of childhood-onset epilepsy in patients who are concurrently taking caffeine | |
| US11925645B2 (en) | Enhanced caffeinated beverage composition | |
| US7476406B1 (en) | Multifaceted weight control system | |
| US8518458B2 (en) | Tea-derived compositions and methods of using same for cardiovascular health | |
| JP2003286167A (ja) | エピガロカテキンガレートを含有するアセチルコリンエステラーゼ阻害剤、薬学的製剤及び食品 | |
| KR20090007281A (ko) | 소양증 및 염증을 억제·완화하기 위한 의약 및 기능성 식품 | |
| CN115279197A (zh) | 增强型含咖啡因饮料组合物 | |
| UA129270C2 (uk) | Композиція тразодону педіатричного призначення | |
| KR101864384B1 (ko) | 콜린 알포세레이트를 유효성분으로 하는 쥐남의 치료, 개선 또는 예방용 조성물 및 방법 | |
| US20090214682A1 (en) | Composition and methods for weight loss in a subject | |
| US11439603B2 (en) | Compositions for ameliorating, preventing or treating somnipathy including phloroglucinol as active ingredient and compositions for suppressing intolerance to or alleviating side effects of agonist at benzodiazepine binding site of GABA-A receptor including phloroglucinol as active ingredient | |
| US11173143B2 (en) | Composition for decreasing serum uric acid level | |
| KR101841654B1 (ko) | 콜린 알포세레이트를 유효성분으로 하는 신경병증성 통증의 치료, 개선 또는 예방용 조성물 및 방법 | |
| EP3651770B1 (en) | Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine | |
| JPH06340542A (ja) | 薬用植物由来の骨疾患の予防・治療剤 | |
| JPH0551320A (ja) | 肝機能改善剤 | |
| KR20140057705A (ko) | 폴리코사놀을 유효성분으로 하는 히스타민 수용체 길항제 조성물 | |
| KR20230141267A (ko) | 원지 추출물 및 인진쑥 추출물의 혼합물을 유효성분으로 함유하는 항비만 및 간손상 억제용 조성물 | |
| KR20200052043A (ko) | 애기 기린초 추출물을 유효성분으로 포함하는 인지능력 개선, 및 퇴행성 뇌질환 예방 또는 치료용 약학적 조성물 및 이의 제조 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO JAZZ PHARMACEUTICALS RESEARCH UK LIMITED |